Fischer, Urs; Fung, Christian; Beyeler, Seraina; Bütikofer, Lukas; Z'Graggen, Werner; Ringel, Florian; Gralla, Jan; Schaller, Karl; Plesnila, Nikolaus; Strbian, Daniel; Arnold, Marcel; Hacke, Werner; Jüni, Peter; Mendelow, Alexander David; Stapf, Christian; Al-Shahi Salman, Rustam; Bressan, Jenny; Lerch, Stefanie; Bassetti, Claudio L. A.; Mattle, Heinrich P; ... (2024). Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial. (In Press). European stroke journal(23969873241231047), p. 23969873241231047. Sage 10.1177/23969873241231047
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
fischer-et-al-2024-swiss-trial-of-decompressive-craniectomy-versus-best-medical-treatment-of-spontaneous-supratentorial.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (684kB) | Request a copy |
RATIONALE
Decompressive craniectomy (DC) is beneficial in people with malignant middle cerebral artery infarction. Whether DC improves outcome in spontaneous intracerebral haemorrhage (ICH) is unknown.
AIM
To determine whether DC without haematoma evacuation plus best medical treatment (BMT) in people with ICH decreases the risk of death or dependence at 6 months compared to BMT alone.
METHODS AND DESIGN
SWITCH is an international, multicentre, randomised (1:1), two-arm, open-label, assessor-blinded trial. Key inclusion criteria are age ⩽75 years, stroke due to basal ganglia or thalamic ICH that may extend into cerebral lobes, ventricles or subarachnoid space, Glasgow coma scale of 8-13, NIHSS score of 10-30 and ICH volume of 30-100 mL. Randomisation must be performed <66 h after onset and DC <6 h after randomisation. Both groups will receive BMT. Participants randomised to the treatment group will receive DC of at least 12 cm in diameter according to institutional standards.
SAMPLE SIZE
A sample of 300 participants randomised 1:1 to DC plus BMT versus BMT alone provides over 85% power at a two-sided alpha-level of 0.05 to detect a relative risk reduction of 33% using a chi-squared test.
OUTCOMES
The primary outcome is the composite of death or dependence, defined as modified Rankin scale score 5-6 at 6 months. Secondary outcomes include death, functional status, quality of life and complications at 180 days and 12 months.
DISCUSSION
SWITCH will inform physicians about the outcomes of DC plus BMT in people with spontaneous deep ICH, compared to BMT alone.
TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT02258919.
Actions (login required)
 |
Edit item |